Shield Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	49.7	32.18	13.09	5.5	2.06
Revenue Growth (YoY)	54.45%	145.93%	137.95%	167.36%	-85.50%
Cost of Revenue	26.66	17.25	9.06	3.04	1.33
Gross Profit	23.04	14.93	4.03	2.46	0.73
Selling, General & Admin	31.59	36.01	37.96	33.65	27.28
Research & Development	1.54	1.89	1.81	1.32	1.08
Other Operating Expenses	-0.04	-0.1	-4.41	-0.86	-0.15
Operating Expenses	33.09	37.8	35.36	34.1	28.21
Operating Income	-10.05	-22.87	-31.33	-31.65	-27.48
Interest Expense	-7.42	-3.87	-1.02	-0.4	-
Interest & Investment Income	0.33	0.27	0.52	0.04	0.02
Currency Exchange Gain (Loss)	-	-0.08	-0.54	0.85	0.52
Other Non Operating Income (Expenses)	-	-	-0	-0.08	-0.01
EBT Excluding Unusual Items	-17.14	-26.56	-32.38	-31.24	-26.96
Asset Writedown	-	-	-	-18.11	-
Pretax Income	-17.14	-26.56	-32.38	-49.34	-26.96
Income Tax Expense	0.51	0.63	0.92	0.45	-0.31
Earnings From Continuing Operations	-17.66	-27.18	-33.29	-49.79	-26.65
Net Income	-17.66	-27.18	-33.29	-49.79	-26.65
Net Income to Common	-17.66	-27.18	-33.29	-49.79	-26.65
Shares Outstanding (Basic)	883	783	723	233	204
Shares Outstanding (Diluted)	883	783	723	233	204
Shares Change (YoY)	12.77%	8.33%	209.85%	14.08%	74.36%
EPS (Basic)	-0.02	-0.03	-0.05	-0.21	-0.13
EPS (Diluted)	-0.02	-0.03	-0.05	-0.21	-0.13
Free Cash Flow	-3.4	-6.81	-37.37	-22.66	-25.23
Free Cash Flow Per Share	-0.00	-0.01	-0.05	-0.10	-0.12
Gross Margin	46.36%	46.39%	30.78%	44.70%	35.48%
Operating Margin	-20.22%	-71.08%	-239.44%	-575.49%	-1336.01%
Profit Margin	-35.52%	-84.47%	-254.44%	-905.42%	-1295.46%
Free Cash Flow Margin	-6.85%	-21.15%	-285.56%	-411.98%	-1226.73%
EBITDA	-8.94	-22.38	-31.08	-29.67	-25.39
EBITDA Margin	-17.98%	-69.56%	-237.51%	-	-
D&A For EBITDA	1.12	0.49	0.25	1.97	2.09
EBIT	-10.05	-22.87	-31.33	-31.65	-27.48
EBIT Margin	-20.22%	-71.08%	-239.44%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.